Ultragenyx Pharmaceutical Inc. has entered into a material agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million. The company was awarded the PRV by the FDA in September 2026 upon the approval of its drug FAYUVI™ for Sanfilippo syndrome Type A.
Key Details
- Agreement Date: October 8, 2026
- Sale Price: $203 million, payable in cash upon closing.
- Asset Origin: The PRV was granted by the FDA on September 17, 2026, following the approval of FAYUVI™ (rebisufligene etisparvovec-hopf) for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA).
- Closing Conditions: The transaction is subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.